Cardiology - Reviews Open access

Heart failure outcomes among reduced and preserved ejection fraction patients on sodium-glucose cotransporter-2 inhibitors with different dosing patterns of diuretics: a systematic review and meta-analysis

Authors

Published
26 February 2026
Issue
Early Access
Section
Cardiology - Reviews

Abstract

The current review was conducted to provide information on the best dosing strategy of background loop diuretics with sodium-glucose cotransporter-2 inhibitors (SGLT2i) for heart failure and safety outcomes among reduced and preserved ejection fraction patients with comorbid conditions. The search was conducted in four databases. Study eligibility was evaluated independently, and a total of four randomized controlled trials were included in this review. Data extraction was performed using the Cochrane-modified extraction template. Statistical analyses and risk of bias assessment were conducted with RevMan version 5.4.1, while the certainty of evidence was appraised using the GRADEpro tool. The primary composite outcomes and hospitalization or urgent heart failure (HF) with SGLT2i and placebo were consistent across all the doses of loop diuretics. The primary composite outcome when loop diuretics were dosed at <40 mg and >40 mg [hazard ratio (HR): 0.77 and HR: 0.81] and showed high significance (p=0.0002), similar for hospitalization and urgent HF (HR: 0.73 and HR: 0.81) with (p=0.0007 and p=0.002). However, when the loop diuretics were dosed at 40 mg, they showed highly significant (p<0.01) efficacies for all cardiovascular outcomes, such as primary composite outcome (HR: 0.76), hospitalization or urgent HF (HR: 0.68), and mortality due to any cause (HR: 0.81), and marginally significant efficacy (p=0.05) for cardiovascular death (HR: 0.86). Compared to the SGLT2i and placebo groups, patients receiving SGLT2i with 40 mg of loop diuretics and placebo were less likely to experience volume depletion, with the odds ratio of 1.56 (p<0.05). The adverse renal effects and discontinuation of the drug were the same across all the doses of loop diuretics. We conclude that SGLT2i plus dosing of loop diuretics at 40 mg with placebo among heart failure patients demonstrated superior cardiovascular and safety outcomes.

References

  1. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-87. DOI: https://doi.org/10.1093/cvr/cvac013
  2. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther 2021;11:263-76. DOI: https://doi.org/10.21037/cdt-20-302
  3. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail 2019;25:584-619. DOI: https://doi.org/10.1016/j.cardfail.2019.05.007
  4. Khan MS, Samman Tahhan A, Vaduganathan M, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail 2020;22:1032-42. DOI: https://doi.org/10.1002/ejhf.1818
  5. Gerhardt T, Gerhardt LMS, Ouwerkerk W, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. Lancet Glob Health 2023;11:e1874-84. DOI: https://doi.org/10.1016/S2214-109X(23)00408-4
  6. Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev 2023;28:585-96. DOI: https://doi.org/10.1007/s10741-022-10238-6
  7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022;79:e263-421.
  8. Jasinska-Piadlo A, Campbell P. Management of patients with heart failure and preserved ejection fraction. Heart 2023;109:874-83. DOI: https://doi.org/10.1136/heartjnl-2022-321097
  9. Berliner D, Hänselmann A, Bauersachs J. The treatment of heart failure with reduced ejection fraction. Dtsch Arztebl Int 2020;117:376-86. DOI: https://doi.org/10.3238/arztebl.2020.0376
  10. Paraskevaidis I, Xanthopoulos A, Karamichalakis N, et al. Medical treatment in heart failure with reduced ejection fraction: a proposed algorithm based on the patient’s electrolytes and congestion status. Med Sci 2023;11:38. DOI: https://doi.org/10.3390/medsci11020038
  11. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. DOI: https://doi.org/10.1002/ejhf.2333
  12. Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020;142:1040-54. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.047077
  13. Butler J, Usman MS, Filippatos G, et al. Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-preserved trial. JAMA Cardiol 2023;8:640-9. DOI: https://doi.org/10.1001/jamacardio.2023.1090
  14. Dhingra NK, Verma S, Butler J, et al. Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: post-hoc analysis of EMPEROR-reduced. JACC Heart Fail 2024;12:35-46. DOI: https://doi.org/10.1016/j.jchf.2023.06.036
  15. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 2022;18:e1230. DOI: https://doi.org/10.1002/cl2.1230
  16. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane. Available from: www.training.cochrane.org/handbook.
  17. PROSPERO International prospective register of systematic reviews. CRD42024581902. Available from: https://www.crd.york.ac.uk/prospero/.
  18. Chatur S, Vaduganathan M, Claggett B, et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J 2023;44:2930-43. DOI: https://doi.org/10.1093/eurheartj/ehad283
  19. Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol 2024;21:717-34. DOI: https://doi.org/10.1038/s41569-024-01046-6
  20. Wu L, Rodriguez M, El Hachem K, Krittanawong C. Diuretic treatment in heart failure: a practical guide for clinicians. J Clin Med 2024;13:4470. DOI: https://doi.org/10.3390/jcm13154470
  21. Biegus J, Zymliński R, Ponikowski P. Loop diuretics in heart failure: The objective markers to guide the therapy are needed. ESC Heart Fail 2024;11:1816-8. DOI: https://doi.org/10.1002/ehf2.14920
  22. Pius R, Odukudu GO, Olorundare I, et al. A narrative review on the efficacy and safety of loop diuretics in patients with heart failure with reduced ejection fraction and preserved ejection fraction. Cureus 2023;15:e45794. DOI: https://doi.org/10.7759/cureus.45794
  23. Lin YH, Tsai WC, Chiu CC, et al. The beneficial effect of the SGLT2 inhibitor dapagliflozin in alleviating acute myocardial infarction-induced cardiomyocyte injury by increasing the sirtuin family SIRT1/SIRT3 and cascade signaling. Int J Mol Sci 2024;25:8541. DOI: https://doi.org/10.3390/ijms25158541
  24. Prosperi S, D'Amato A, Severino P, et al. Sizing SGLT2 inhibitors up: from a molecular to a morpho-functional point of view. Int J Mol Sci 2023;24:13848. DOI: https://doi.org/10.3390/ijms241813848
  25. Charaya K, Shchekochikhin D, Andreev D, et al. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart 2022;9:e001936. DOI: https://doi.org/10.1136/openhrt-2021-001936
  26. Carvalho PEP, Veiga TMA, Simões E Silva AC, et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol 2023;112:1044-55. DOI: https://doi.org/10.1007/s00392-022-02148-2
  27. lsalem A, Alsultan MM, Alqarni F, et al. Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study. Front Pharmacol 2024;15:1366439. DOI: https://doi.org/10.3389/fphar.2024.1366439
  28. Kapelios CJ, Bonou M, Malliaras K, et al. Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients. Heart Fail Rev 2022;27:147-61. DOI: https://doi.org/10.1007/s10741-020-09995-z
  29. Alshibani M, Alshehri S, Alyazidi W, et al. The impact of discharged loop diuretic dose to home dose on hospital readmissions in patients with acute decompensated heart failure: a retrospective cohort study. Heart Surg Forum 2020;23:E470-4. DOI: https://doi.org/10.1532/hsf.3029

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.